Daratumumab for kidney disease caused by abnormal proteins
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your kidney biopsy shows MGRS (a type of kidney disease from abnormal proteins).
- You have significant protein in your urine (≥500 mg per day) or your kidney function is at least 20 ml/min.
- You have not had certain chemotherapies recently (like cyclophosphamide within 6 months, or high-dose steroids within 6 weeks).
- You do not have active infections like HIV, hepatitis B or C (or they are well controlled).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
This trial tests a combination of two drugs (daratumumab and bortezomib, plus a steroid called dexamethasone) for people with rare kidney conditions caused by abnormal proteins. The treatment targets the abnormal plasma cells to help protect your kidneys and improve your health.
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This trial tests a combination of four medications (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with monoclonal immunoglobulin deposition disease (MIDD), a condition where abnormal proteins build up in organs. The goal is to see if this treatment can help without prior harsh therapies.
This trial tests a drug called daratumumab for people with aplastic anemia that hasn't improved with standard treatments. The goal is to see if it can help your bone marrow make more blood cells and improve your blood counts.
Hear when a new Kidney Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.